Company

ABOUT TEIKOKU PHARMA

Teikoku Pharma USA (TPU), a subsidiary of Teikoku Seiyaku, Japan, is a family-owned, privately-held international specialty pharmaceutical company founded in 1997 in California.

We develop innovative products in several therapeutic areas, including pain management, CNS disorders, dermatology, and oncology, using our proprietary and innovative drug delivery platforms, including patches, injectables, gels, creams, and ointments. Our team can take an asset from conception to FDA approval, including R&D, clinical, regulatory, and manufacturing.

OUR HISTORY

Teikoku Seiyaku has a storied history of technological innovation and business success.

1848
1918
1938
1957
1974
1975
1985
1988
1993
1995
1997
1999
2003
2007
2009
2015

1848

Shozo Akazawa, the 5th head of the family, is certified by the government to deal in medicines, and starts the business.

1918

Teikoku Seiyaku is established with 1 million yen in capital in Kagawa Prefecture, Japan.

1938

Horxis launches in Japan, a prototype of the current medicated plaster.

1957

Osaka Plant spins off of Teikoku Seiyaku, and with it, Fuso Chemical Industry Co. Ltd.

1974

Teikoku Seiyaku’s medicated plasters are approved for prescription use, becoming the company’s main product line.

1975

The first stage of the new production plant for plasters is completed. The final stage of construction is completed in 1978.

1985

Teikoku Kampo Seiyaku Co. Ltd, Teikoku’s subsidiary company that specializes in herbal medicine, is established.

1988

Catlep, Japan’s first transdermal indomethacin plaster for prescription use, is approved and production begins.

1993

Seltouch, a transdermal felbinac plaster for prescription use, is approved and production begins.

1995

Non-prescription drug division (OTC) spins off as an independent company, Teikoku Pharmacare, Co. Ltd.

1997

Teikoku Pharma USA is established.

1999

FDA grants approval for Lidoderm in the US.

2003

Fuso Teiyaku is established in Qingdao, China.

2007

Versatis receives MHRA approval in UK, and Flector receives FDA approval in the US.

2009

TPU acquires Travanti Pharma.

2015

FDA grants approval for Docetaxel Non-Alcohol Formula in the US.

Parent Company

Teikoku Seiyaku is a world leader in the research, development, manufacture, and commercialization of pharmaceutical drugs.

Management Team

Our company is guided by deep experience and expertise.

Scientific Advisory Board

Our work is guided by expert scientists and researchers in their fields.

Partnerships

See what opportunities are possible when you partner with Teikoku Pharma.

Affiliates

Learn about Teikoku Group and our mission to deliver innovative and safe drug delivery solutions.

Careers

Help us improve the lives of patients by joining our growing team.

FEATURED NEWS

News

Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.

News

Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

News

Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China

News

Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China

News

Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery

News

Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula